GlassScriptPhysician profile
Jeremiah Dell
NPI 1346528379
$4,587.56
in general payments reported to CMS, 2019-2025
14 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $81.38 · 2021: $641 · 2022: $876 · 2023: $772 · 2024: $627 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,420.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,295.97 | 2021-2025 | Precision 1, Total30, Dailies Total1 |
| Coopervision INC. | $729.87 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Biofinity Contact Lens |
| Bausch & Lomb Americas INC. | $725.65 | 2022-2025 | Infuse |
| Johnson & Johnson Vision Care, INC. | $689.34 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $360.87 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $271.00 | 2019-2021 | |
| Horizon Therapeutics Plc | $98.71 | 2022 | |
| Aerie Pharmaceuticals, INC. | $97.76 | 2021 | |
| Integra Lifesciences Corporation | $96.83 | 2023 | Biodoptix, Medihoney, Biodfactor |
| Optos, INC. | $64.81 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $62.27 | 2019 | |
| Lkc Technologies, INC. | $51.19 | 2023 | |
| Abbvie INC. | $22.75 | 2023 | Vuity, Lumigan |
| Dompe US, INC. | $20.54 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremiah Dell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.